标题
Treatment of MDS
作者
关键词
-
出版物
BLOOD
Volume 133, Issue 10, Pages 1096-1107
出版商
American Society of Hematology
发表日期
2019-01-23
DOI
10.1182/blood-2018-10-844696
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
- (2018) Ronan T. Swords et al. BLOOD
- Getting to transplant in Hodgkin lymphoma: BVB
- (2018) Leo I. Gordon BLOOD
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
- (2018) Pierre Fenaux et al. LEUKEMIA
- H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
- (2018) Michael Seiler et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial
- (2018) Martin Wermke et al. Lancet Haematology
- Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
- (2018) Rami Komrokji et al. Lancet Haematology
- Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
- (2018) Hagop M Kantarjian et al. Lancet Haematology
- Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
- (2018) Anne Kubasch et al. Cancers
- Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
- (2018) Uwe Platzbecker et al. LANCET ONCOLOGY
- Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
- (2017) Sophie Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
- (2017) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2017) Bart L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
- (2017) Nicolaus Kröger et al. JOURNAL OF CLINICAL ONCOLOGY
- Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
- (2017) Uwe Platzbecker et al. LANCET ONCOLOGY
- A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
- (2017) U Platzbecker et al. LEUKEMIA
- Decitabine in TP53-Mutated AML
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
- (2017) R. Coleman Lindsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors
- (2017) Anna Mies et al. SEMINARS IN HEMATOLOGY
- CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
- (2017) Claudia Brunetti et al. Expert Review of Hematology
- Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
- (2017) Hee Sue Park et al. Annals of Laboratory Medicine
- Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
- (2017) Esther N Oliva et al. Lancet Haematology
- Time-dependent changes in mortality and transformation risk in MDS
- (2016) Michael Pfeilstöcker et al. BLOOD
- Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
- (2016) M Robin et al. BONE MARROW TRANSPLANTATION
- TP53mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes
- (2016) Chun-Kang Chang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
- (2016) Christian Scharenberg et al. HAEMATOLOGICA
- A randomized phase II trial of azacitidine +/- epoetin- in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
- (2016) S. Thepot et al. HAEMATOLOGICA
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
- (2016) Valeria Santini et al. JOURNAL OF CLINICAL ONCOLOGY
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
- (2016) Guillermo Garcia-Manero et al. LANCET ONCOLOGY
- Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
- (2016) M Mossner et al. LEUKEMIA
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
- (2016) Christian Scharenberg et al. HAEMATOLOGICA
- A randomized phase II trial of azacitidine +/- epoetin- in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
- (2016) S. Thepot et al. HAEMATOLOGICA
- Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
- (2016) David A. Sallman et al. Frontiers in Oncology
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
- (2015) M. Meggendorfer et al. HAEMATOLOGICA
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
- (2015) D A Sallman et al. LEUKEMIA
- HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
- (2015) M Robin et al. LEUKEMIA
- Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
- (2015) U Oelschlaegel et al. LEUKEMIA
- Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
- (2015) A Toma et al. LEUKEMIA
- Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia
- (2015) M. Meggendorfer et al. HAEMATOLOGICA
- Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis
- (2014) Philippe Armand et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
- (2014) Aristoteles Giagounidis et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Myelodysplasia is in the niche: novel concepts and emerging therapies
- (2014) E Bulycheva et al. LEUKEMIA
- Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
- (2014) U Platzbecker et al. LEUKEMIA
- Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
- (2014) M Tobiasson et al. Blood Cancer Journal
- Allogeneic stem cell transplantation in MDS: How? When?
- (2013) Uwe Platzbecker et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
- (2013) V. Santini et al. BLOOD
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
- (2013) L. Malcovati et al. BLOOD
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- (2013) Yun-Gyoo Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
- (2013) U Platzbecker et al. LEUKEMIA
- Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
- (2013) C Kelaidi et al. LEUKEMIA
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
- (2013) T Haferlach et al. LEUKEMIA
- Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
- (2012) Uwe Platzbecker et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS
- (2012) H. J. Deeg et al. BLOOD
- MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
- (2012) M. Wermke et al. CLINICAL CANCER RESEARCH
- Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
- (2012) Gandhi Damaj et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
- (2012) Arjan A. van de Loosdrecht et al. LEUKEMIA & LYMPHOMA
- The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
- (2012) Uwe Platzbecker et al. LEUKEMIA RESEARCH
- Immunomodulatory Treatment of Myelodysplastic Syndromes: Antithymocyte Globulin, Cyclosporine, and Alemtuzumab
- (2012) Ankur R. Parikh et al. SEMINARS IN HEMATOLOGY
- Upfront Allogeneic Blood Stem Cell Transplantation for Patients with High-Risk Myelodysplastic Syndrome or Secondary Acute Myeloid Leukemia Using a FLAMSA-Based High-Dose Sequential Conditioning Regimen
- (2011) Christian Saure et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- (2011) P. Fenaux et al. BLOOD
- Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
- (2011) T. Braun et al. BLOOD
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
- (2011) A A N Giagounidis et al. LEUKEMIA
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iron overload in MDS—pathophysiology, diagnosis, and complications
- (2010) Norbert Gattermann et al. ANNALS OF HEMATOLOGY
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
- (2010) Elaine M. Sloand et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)
- (2008) Uwe Platzbecker et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now